Community Practice Connections™: Advances in CAR T-Cell Therapy: What Does the Future Look Like?

Release Date: January 28, 2021
Expiration Date: January 28, 2022

Activity Overview

Community Practice Connections^TM: Advances in CAR T-Cell Therapy: What Does the Future Look Like? consists of a series of short summaries of clinical data and concise video interviews with leading experts in chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The video interviews provide expert perspectives on clinical data and address questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Kite Pharma and Novartis Pharmaceuticals Corporation.

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate current clinical data and emerging approaches with CAR T-cell therapy for the management of patients with hematologic malignancies
• Discuss criteria for selection of patients for CAR T-cell therapy and best practices for referral and follow-up of patients from community practices
• Incorporate strategies to mitigate and manage treatment-related adverse events in patients undergoing CAR T-cell therapy
• Describe the role of advanced practitioners in counseling patients and caregivers on expectations during CAR T-cell therapy, and in improving patient care through communication with both the patient and the multidisciplinary care team

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

David G. Maloney, MD, PhD
Professor, Clinical Research Division
Medical Director, Cellular Immunotherapy
Leonard and Norma Klorfine Endowed Chair for Clinical Research
Fred Hutchinson Cancer Research Center
Professor of Medicine, Division of Oncology
University of Washington
Seattle, WA

Disclosures: Grant Research Support: Kite Pharma, Juno Therapeutics, Celgene; Consultant: A2 Biotherapeutics, Amgen, BioLine Rx, Bristol Myers Squibb, Juno Therapeutics, Celgene, Gilead Sciences, MorphoSys, Novartis, Genentech, Legend Biotech, Janssen; Other: Patents Pending - Juno Therapeutics; Stock Options - A2 Biotherapeutics

Matthew J. Frigault, MD
Clinical Director, Cellular Immunotherapy Program
Massachusetts General Hospital
Boston, MA

Disclosures:  Grant Research Support: Kite Pharma, Novartis; Consultant: Arcellx, Novartis, Bristol Myers Squibb/Celgene, Kite Pharma/Gilead Sciences, Takeda

Stephanie Jackson, MSN, RN, AOCNS, BMTCN
Oncology Clinical Nurse Specialist/Unit Director (New Transition)
Ronald Reagan UCLA Medical Center
Los Angeles, CA

Disclosures: Consultant: Jazz Pharmaceuticals

Krishna V. Komanduri, MD
Chief, Division of Transplantation and Cellular Therapy
Kalish Family Chair in Stem Cell Transplantation
Professor of Medicine, Microbiology, and Immunology
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL

Disclosures: Grant Research Support: To University of Miami for clinical trials: Kite Pharma, Adaptimmune, Autolus Therapeutics, Cartesian Therapeutics, Iovance Biotherapeutics, Novartis, Bristol Myers Squibb, Allogene Therapeutics, Incyte, Janssen; Consultant: Kite Pharma, Novartis, Takeda, Autolus Therapeutics, Incyte, Iovance Biotherapeutics, Kiadis Pharma, Kadmon, Gamida Cell, Genentech, Helocyte.

Jeff Sharman, MD
Director of Research
Willamette Valley Cancer Institute and Research Center
Medical Director of Hematology Research
The US Oncology Network
Eugene, OR

Disclosures: Grant Research Support: Juno Therapeutics, Celgene, Bristol Myers Squibb, AbbVie, Genentech, Pharmacyclics, AstraZeneca; Consultant: Juno Therapeutics, Celgene, Bristol Myers Squibb, AbbVie, Janssen, Genentech, Pharmacyclics, AstraZeneca

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.